食管胃腺癌的免疫治疗
Immunotherapy in Esophagogastric Adenocarcinoma.
作者信息
Stein Alexander, Thuss-Patience Peter
机构信息
University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Charité, University Medicine Berlin, Berlin, Germany.
出版信息
Visc Med. 2019 Mar;35(1):12-16. doi: 10.1159/000497292. Epub 2019 Feb 7.
Abstract
Immunotherapy, particular PD-1/L1 inhibition, is a relevant treatment approach in esophagogastric adenocarcinoma. To date, single-agent activity is limited to the chemotherapy refractory setting and molecularly defined subgroups. Currently, ongoing trials, which are likely to relevantly change the landscape of treatment for this disease in the next years, evaluate different combination approaches with chemotherapy and/or molecular targeted agents in different disease settings. The German AIO study group has launched several combination trials in the perioperative, first-line, and advanced disease setting to further define the role of immunotherapy in esophagogastric adenocarcinoma.
摘要
免疫疗法，尤其是PD-1/L1抑制，是食管胃腺癌的一种相关治疗方法。迄今为止，单药活性仅限于化疗难治性情况和分子定义的亚组。目前，正在进行的试验可能会在未来几年显著改变这种疾病的治疗格局，这些试验在不同疾病情况下评估与化疗和/或分子靶向药物的不同联合方法。德国AIO研究小组已在围手术期、一线和晚期疾病情况下开展了多项联合试验，以进一步明确免疫疗法在食管胃腺癌中的作用。
相似文献
1
Immunotherapy in Esophagogastric Adenocarcinoma.食管胃腺癌的免疫治疗
Visc Med. 2019 Mar;35(1):12-16. doi: 10.1159/000497292. Epub 2019 Feb 7.
2
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).Ipilimumab 或 FOLFOX 联合 Nivolumab 和 Trastuzumab 治疗未经治的 HER2 阳性局部晚期或转移性胃食管腺癌 - 随机 2 期 INTEGA 试验（AIO STO 0217）。
BMC Cancer. 2020 Jun 1;20(1):503. doi: 10.1186/s12885-020-06958-3.
3
Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.晚期/转移性食管胃腺癌免疫治疗的最新进展与当前挑战
Eur J Cancer. 2022 Nov;176:13-29. doi: 10.1016/j.ejca.2022.08.023. Epub 2022 Sep 29.
4
Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.PD-1抑制剂在晚期胃食管交界癌和胃癌一线治疗中按亚组分析的疗效：一项系统评价和荟萃分析
Chemotherapy. 2023;68(4):197-209. doi: 10.1159/000531457. Epub 2023 Jun 16.
5
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.晚期胃癌和食管胃交界腺癌的挽救性全身治疗
Cochrane Database Syst Rev. 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2.
6
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).可切除胃癌的围手术期治疗：Spartalizumab 联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛（FLOT）：一项 II 期研究（GASPAR）。
BMC Cancer. 2022 May 12;22(1):537. doi: 10.1186/s12885-022-09623-z.
7
A study protocol of a randomized phase II trial of perioperative chemoimmunotherapy verses perioperative chemoimmunotherapy plus preoperative chemoradiation for locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma: the NeoRacing study.一项针对局部进展期胃（G）或胃食管结合部（GEJ）腺癌行围手术期化疗免疫治疗与围手术期化疗免疫治疗联合术前放化疗的随机 II 期临床试验方案：NeoRacing 研究。
BMC Cancer. 2022 Jun 28;22(1):710. doi: 10.1186/s12885-022-09786-9.
8
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321).帕博利珠单抗和曲妥珠单抗联合FLOT用于HER2阳性局部食管胃腺癌围手术期治疗——AIO研究组的一项II期试验（AIO STO 0321）
Front Oncol. 2023 Oct 16;13:1272175. doi: 10.3389/fonc.2023.1272175. eCollection 2023.
9
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.多线治疗可改善晚期胃食管腺癌患者的生存状况：一项超过 500 例患者分析结果
Clin Colorectal Cancer. 2018 Sep;17(3):223-230. doi: 10.1016/j.clcc.2018.05.014. Epub 2018 Jun 8.
10
Immunotherapy in esophagogastric cancer.免疫疗法在胃食管交界处癌中的应用。
Clin Adv Hematol Oncol. 2021 Oct;19(10):639-647.
引用本文的文献
1
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.c-Myb 通过 miR-145-5p/SPOP/PD-L1 轴促进食管腺癌细胞的免疫逃逸。
Clin Transl Med. 2021 Sep;11(9):e464. doi: 10.1002/ctm2.464.
2
Optimized PD-L1 scoring of gastric cancer.优化胃癌 PD-L1 评分。
Gastric Cancer. 2021 Sep;24(5):1115-1122. doi: 10.1007/s10120-021-01195-4. Epub 2021 May 5.
3
Immunotherapy in Gastrointestinal Cancer: Where Do We Stand?胃肠道癌的免疫疗法：我们目前的进展如何？
Visc Med. 2019 Mar;35(1):1-2. doi: 10.1159/000497294. Epub 2019 Feb 8.
本文引用的文献
1
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.CheckMate-032 研究：纳武利尤单抗和纳武利尤单抗联合伊匹单抗治疗转移性胃食管交界部癌患者的疗效和安全性。
J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15.
2
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.avelumab 对比医师选择的化疗作为晚期胃癌或胃食管结合部癌三线治疗的 III 期随机试验：JAVELIN Gastric 300 的主要分析结果
Ann Oncol. 2018 Oct 1;29(10):2052-2060. doi: 10.1093/annonc/mdy264.
3
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.PD-1 抑制治疗转移性胃癌的临床反应的全面分子特征分析。
Nat Med. 2018 Sep;24(9):1449-1458. doi: 10.1038/s41591-018-0101-z. Epub 2018 Jul 16.
4
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比紫杉醇用于治疗晚期或胃食管结合部腺癌（KEYNOTE-061）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.
5
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
6
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.抗程序性死亡受体-1 抗体派姆单抗治疗晚期食管癌患者的安全性和抗肿瘤活性。
J Clin Oncol. 2018 Jan 1;36(1):61-67. doi: 10.1200/JCO.2017.74.9846. Epub 2017 Nov 8.
7
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
8
Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.序贯伊匹单抗单药治疗与最佳支持治疗不可切除局部晚期/转移性胃或胃食管结合部癌的疗效。
Clin Cancer Res. 2017 Oct 1;23(19):5671-5678. doi: 10.1158/1078-0432.CCR-17-0025. Epub 2017 Jun 27.
9
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.曲妥珠单抗-美坦新偶联物对比紫杉烷类药物用于既往治疗的人表皮生长因子受体 2（HER2）阳性局部晚期或转移性胃或胃食管结合部腺癌（GATSBY）：一项国际、随机、开放标签、适应性、2/3 期研究。
Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23.
10
Integrated genomic characterization of oesophageal carcinoma.食管癌的综合基因组特征分析
Nature. 2017 Jan 12;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4.
Zotero 插件